ALX Oncology Finalizes $150M Public Offering with Significant Dilution and Pre-Funded Warrants

summarizeSummary

ALX Oncology Holdings Inc. finalized a $150 million public offering of common stock and pre-funded warrants, representing a substantial capital raise at a discount to the current market price, which will significantly dilute existing shareholders and address going concern risks.

check_boxKey Events · Financing and Capital Events · ALXO

• Finalizes Terms of $150 Million Public Offering

  This prospectus supplement details the pricing and terms of the underwritten public offering announced earlier today, January 30, 2026, for approximately $150 million.

• Massive Share Dilution

  The offering of 76.98 million common shares and 18.57 million pre-funded warrants will increase outstanding shares by approximately 178% and is equivalent to 159% of the company's current market capitalization.

• Addresses Going Concern Risk

  The company explicitly stated that without these proceeds, there would be substantial doubt about its ability to continue as a going concern, highlighting the critical need for capital.

• Extends Financial Runway

  Net proceeds of $140.4 million are expected to fund operations through the first half of 2028.

auto_awesomeAnalysis · ALXO · Life Sciences

This 424B5 filing finalizes the detailed terms of the underwritten public offering, which was announced earlier today, January 30, 2026, via an 8-K. The offering involves a highly dilutive capital raise of approximately $150 million, comprising 76.98 million shares of common stock and pre-funded warrants to purchase an additional 18.57 million shares. This substantial issuance represents an increase of approximately 178% over the previously outstanding shares and is equivalent to 159% of the company's current market capitalization. The common stock is priced at $1.57 per share and the pre-funded warrants at $1.569, both at a discount to the current stock price of $1.74. The company explicitly stated that "Absent the net proceeds from this offering, there would have been substantial doubt as to our ability to continue as a going concern," underscoring the critical nature of this financing. While the net proceeds of $140.4 million are projected to fund operations through the first half of 2028, the extreme dilution and the distressed context of the offering are significantly negative for existing shareholders and will likely exert considerable downward pressure on the stock.